



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2020-21
October 23, 2020

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East),
Mumbai – 400051
NSE CODE: AARTIDRUGS

Dear Sir/Madam,

Ref: Para A of Part A of Schedule III of the SEBI (LODR)
Regulations, 2015.

Sub: Outcome of the Board Meeting – Fund Raising

We refer our letter dated October 20, 2020 on captioned subject.

In this connection, we wish to inform you that the Board of Directors of the Company, at its meeting held on today, has inter alia passed an enabling resolution for raising of funds by way of issue of equity shares or any other instruments or security including fully/partly convertible debentures or by way of a composite issue of non-convertible debentures and warrants entitling the warrant holder(s) to apply for equity shares or any other eligible securities through qualified institutions placement, private placement/public issue of equity/debt securities, preferential issue or through any other permissible mode and/or combination thereof as may be considered appropriate, subject to such approvals as may be required including the approval of the members at a general meeting or through postal ballot and further subject to such other statutory/regulatory approvals, as applicable for an aggregate amount **of upto Rs. 350 Crores (Rupees Three hundred and Fifty Crores).**

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: A54527



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2020-21

October 23, 2020

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East),
Mumbai – 400051
NSE CODE: AARTIDRUGS

Dear Sir/Madam,

Ref: Compliance of Regulation 33 and Regulation 30 of SEBI (LODR) Regulations, 2015.

Sub: Audited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2020.

We wish to inform you that Board of Directors at its Meeting held on **Friday, October 23, 2020**, approved the Audited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2020.

Pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015 we enclose the following:-

- Audited Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2020.
- Auditor’s Report on Standalone and Consolidated Financial Results for the Quarter and Half year ended September 30, 2020.

Further, please note that the Company has already made necessary arrangement to publish the same in the Newspapers as required under the SEBI (LODR) Regulations, 2015.

Meeting of the Board of Directors commenced at 12:00 Noon and concluded at 3:30 PM

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER


ICSI M. No.: A54527

AARTI DRUGS LIMITED
STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th September' 2020

Sr. No.	Particulars	Standalone						(Rs. in lakhs except for share data)					
		Quarter Ended			Period Ended			Quarter Ended			Period Ended		
		30th Sep 2020 (Audited)	30th Jun 2020 (Audited)	30th Sep 2019 (Audited)	30th Sep 2020 (Audited)	30th Sep 2019 (Audited)	31st Mar 2020 (Audited)	30th Sep 2020 (Audited)	30th Jun 2020 (Audited)	30th Sep 2019 (Audited)	30th Sep 2020 (Audited)	30th Sep 2019 (Audited)	31st Mar 2020 (Audited)
I	Revenue from operations	51,516	47,555	44,271	99,071	81,273	1,63,492	57,811	54,467	47,750	1,12,277	88,293	1,80,609
II	Other income	26	124	21	150	31	106	29	126	19	155	25	148
III	Total Income (I + II)	51,542	47,679	44,292	99,221	81,305	1,63,598	57,840	54,593	47,769	1,12,433	88,319	1,80,757
IV	Expenses :												
	(a) Cost of materials consumed	30,325	27,788	28,721	58,114	54,725	1,07,880	32,611	29,803	30,175	62,414	58,032	1,14,192
	(b) Purchase of stock-in-trade	1,137	855	879	1,992	1,843	4,053	3,450	2,678	1,688	6,128	3,393	8,832
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(216)	(450)	(406)	(666)	(3,194)	(5,394)	(244)	(528)	(221)	(773)	(2,871)	(5,128)
	(d) Employee benefits expense	1,928	1,595	1,491	3,524	2,912	6,010	2,213	1,858	1,714	4,072	3,341	6,936
	(e) Finance costs	698	639	808	1,337	1,688	3,220	705	657	854	1,362	1,787	3,373
	(f) Depreciation and amortisation expense	1,197	1,192	1,155	2,389	2,283	4,667	1,256	1,238	1,209	2,495	2,391	4,875
	(g) Other expenses	7,444	6,157	7,064	13,601	13,237	26,503	8,137	7,259	7,564	15,396	14,096	29,596
	Total expenses (IV)	42,514	37,776	39,713	80,290	73,493	1,46,939	48,128	42,965	42,983	91,093	80,169	1,62,675
V	Profit before exceptional items and tax (III - IV)	9,028	9,903	4,580	18,931	7,812	16,660	9,712	11,628	4,787	21,340	8,150	18,082
VI	Exceptional items	-	-	-	-	-	(838)	-	-	-	-	-	(447)
VII	Profit before tax (V - VI)	9,028	9,903	4,580	18,931	7,812	17,497	9,712	11,628	4,787	21,340	8,150	18,529
VIII	Tax Expenses :												
	Provision for taxation - Current	2,200	2,500	1,300	4,700	2,175	4,225	2,373	2,942	1,338	5,315	2,247	4,604
	- MAT credit	-	-	-	-	-	-	-	-	-	-	-	-
	- Earlier year	-	-	-	-	-	-	-	-	-	-	-	-
	Provision for deferred taxation	(150)	100	200	(50)	400	(1,025)	(188)	141	218	(47)	-	730
	Total tax expenses (VIII)	2,050	2,600	1,500	4,650	2,575	3,930	2,185	3,083	1,555	5,268	2,674	4,389
IX	Profit / (Loss) for the Year (VII - VIII)	6,978	7,303	3,080	14,281	5,237	13,567	7,527	8,545	3,231	16,072	5,476	14,140
X	Other Comprehensive Income												
	Item that will not be reclassified to statement of Profit and Loss												
	Fair value changes on Investments, net	-	-	-	-	-	284	-	-	-	-	-	284
	Remeasurement of defined benefit Liability/Assets, net	-	-	-	-	-	(107)	-	-	-	-	-	(107)
	Total Other Comprehensive Income, net	-	-	-	-	-	177	-	-	-	-	-	177
XI	Total Comprehensive Income for the Year (IX+X)	6,978	7,303	3,080	14,281	5,237	13,745	7,527	8,545	3,231	16,072	5,476	14,317
XII	Paid up equity share capital (face value of Rs.10 each)	2,330	2,330	2,330	2,330	2,330	2,330	2,330	2,330	2,330	2,330	2,330	2,330
XIII	Earning per equity share (in Rs.) (not annualised)												
XIV	Profit attributable to :												
	Owner of the Company	6,978	7,303	3,080	14,281	5,237	13,567	7,527	8,545	3,231	16,072	5,476	14,140
	Non- Controlling Interest	-	-	-	-	-	-	-0.45	-0.01	-	-0.46	-	-0.21
XV	Total Comprehensive Income attributable to :												
	Owner of the Company	6,978	7,303	3,080	14,281	5,237	13,745	7,527	8,545	3,231	16,072	5,476	14,317
	Non- Controlling Interest	-	-	-	-	-	-	(0.45)	(0.01)	-	(0.46)	-	(0.21)
	(1) Basic	29.95	31.34	13.22	61.29	22.39	58.12	32.30	36.67	13.87	68.98	23.41	60.57
	(2) Diluted	29.95	31.34	13.22	61.29	22.39	58.12	32.30	36.67	13.87	68.98	23.41	60.57

Place: Mumbai
Date: 23rd October' 2020

For AARTI DRUGS LIMITED


HARSHIT M. SAVLA
(JT. Managing Director)

AARTI DRUGS LIMITED				
STATEMENT OF ASSETS AND LIABILITIES AS AT 30th September' 2020				
Particulars	(Rs. in lakhs)			
	Standalone		Consolidated	
	30th Sept 2020	31st Mar 2020	30th Sept 2020	31st Mar 2020
ASSETS				
1 Non - Current Assets				
Property, Plant and Equipment				
Right of use Assets	62,587	60,156	65,887	63,359
Capital work - in - progress	693	873	693	873
Intangible assets	1,096	1,096	1,161	1,221
Financial Assets	51	129	68	149
Investments				
Other Non- Current Assets	2,038	2,038	1,336	1,336
Total Non- Current Assets	205	242	303	312
2 Current Assets				
Inventories				
Financial Assets	33,664	30,741	35,709	32,540
(i) Trade receivable				
(ii) Cash and cash equivalents	55,348	46,434	60,392	48,863
(iii) Other Current Financial Assets	533	385	1,102	764
Other current assets	1,183	1,189	1,194	1,200
Total Current Assets	5,622	3,787	6,601	6,577
Non current Asset held for sale	96,350	82,536	1,04,997	89,945
TOTAL ASSETS	-	-	-	455
	1,63,019	1,47,070	1,74,447	1,57,650
EQUITY AND LIABILITIES				
1 EQUITY				
Share Capital	2,330	2,330	2,330	2,330
Other Equity	74,130	59,849	79,033	62,919
Total Equity Attributable to Equity Holders of the Company	76,460	62,179	81,363	65,249
Non- Controlling Interests	-	-	-0.68	-0.21
Total Equity	76,460	62,179	81,362	65,249
LIABILITIES				
2 Non-current liabilities				
Financial Liabilities				
(i) Borrowings	15,711	17,628	15,711	18,031
(ii) Other financial liability	1,355	1,443	1,405	1,466
Provisions	3,556	2,362	3,835	2,363
Deferred tax liabilities (Net)	7,809	7,859	8,024	8,071
Total of Non current liabilities	28,431	29,291	28,975	29,931
3 Current liabilities				
Financial Liabilities				
(i) Borrowings				
(ii) Trade payables	17,658	15,461	18,167	15,773
Dues of micro enterprises and small enterprises	885	795	1,360	1,157
Dues of creditors other micro enterprises and small enterprises	29,874	30,842	31,695	31,798
Provisions	452	365	581	459
Other current liabilities	9,259	8,136	12,307	13,283
Total of current liabilities	58,128	55,599	64,110	62,470
TOTAL EQUITY AND LIABILITIES	1,63,019	1,47,070	1,74,447	1,57,650

Notes :

- The above results for the quarter and period ended 30th September, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 23rd October, 2020.
- Pursuant to the approval of the Shareholders accorded through Postal Ballot on September 20, 2020, Authorised Share Capital of the Company has been increased from Rs. 25,00,00,000/- divided into 2,50,00,000 Equity Shares of Face Value of Rs. 10/- each to Rs. 120,00,00,000/- divided into 12,00,00,000 Equity Shares of Face Value of Rs. 10/-each to facilitate the issue of Bonus Shares.
- Pursuant to the approval of the Shareholders accorded through Postal Ballot on September 20, 2020, Company has allotted 6,99,00,000 Bonus Equity Shares of Rs. 10/- each fully paid up on October 5, 2020 in the proportion of 3 Equity Shares for every 1 Equity Share held by the Equity Shareholders of the Company as on the record date of October 1, 2020.
- The Board of Directors have recommended Interim Dividend of Rs.2.5/- per Equity Share of Rs. 10/- each (25%) amounting to Rs.23,30,00,000/- for the Period ended 30th September'2020.
- Company has only one business segment i.e. pharmaceuticals.
- Figures for the previous Quarter have been regrouped or rearranged wherever necessary.
- The aforesaid Audited Financial Results will be uploaded on the Company's website www.aartidrugs.com and will also be available on the website of BSE Limited www.bseindia.com and the National Stock Exchange of India Limited www.nseindia.com for the benefit of the shareholders and investors.

Place: Mumbai
Date: 23rd October' 2020


For AARTI DRUGS LIMITED


HARSHIT M. SAVLA
(JT. Managing Director)

AARTI DRUGS LIMITED					
CASH FLOW STATEMENT AS AT 30th September' 2020 (Rs. in lakhs)					
S.No	Particulars	Standalone		Consolidated	
		30th Sept 2020	31st Mar 2020	30th Sept 2020	31st Mar 2020
A.	Cash Flow from Operating Activities				
	Net Profit before Tax	18,931	17,497	21,340	18,529
	ADJUSTMENT FOR:				
	Depreciation & Amortisation	2,389	4,667	2,495	4,875
	Provision for Doubtful debts /Bad debts	6	268	34	275
	Unrealised Foreign Exchange (Gain)/Loss (Net)	(219)	738	(219)	738
	Interest Paid	1,337	3,220	1,362	3,373
	Interest Received	(2)	(73)	(7)	(131)
	Dividend Received	(92)	(0)	(92)	(0)
	Profit on Sale of Assets	-	(837)	-	(446)
	Operating Profit before Working Capital Changes	22,351	25,480	24,912	27,213
	Trade & Other Receivable	(10,737)	(1,429)	(11,402)	173
	Changes in Inventories	(2,923)	(7,971)	(3,127)	(7,869)
	Trade & Other Payable	182	7,266	(704)	9,645
	Cash generated from operation	8,873	23,346	9,679	29,162
	Direct Taxes Paid	(3,505)	(3,732)	(3,845)	(4,088)
	Net Cash Flow from Operating Activities	5,368	19,615	5,834	25,074
B.	Cash Flow from Investing Activities				
	Purchase of Fixed Assets / Capital Work in Progress/ Advances	(4,526)	(4,708)	(4,694)	(4,799)
	Sale of Fixed Assets/Investments	-	1,700	455	1,347
	Interest Received	2	73	7	131
	Dividend Received	92	0	92	0
	Net Cash Flow from Investing Activities	(4,432)	(2,935)	(4,140)	(3,321)
C.	Cash Flow from Financing Activities				
	Proceeds from Long Term Borrowings	(1,625)	(997)	(2,367)	(2,135)
	Proceeds from Unsecured Loans & from Scheduled Bank	2,196	(9,173)	2,394	(12,647)
	Buy Back of shares	-	(2,539)	-	(2,539)
	Dividend Paid	(11)	(703)	(11)	(703)
	Dividend Tax Paid	(0)	(144)	(0)	(144)
	Interest Paid	(1,337)	(3,220)	(1,362)	(3,373)
	Net Cash Flow from Financing Activities	(777)	(16,776)	(1,346)	(21,541)
	Net Increase in Cash and Cash Equivalents (A+B+C)	159	(96)	348	213
	Opening Cash and Cash Equivalents	298	394	677	464
	Closing Cash and Cash Equivalents	457	298	1,025	677

Place: Mumbai
Date: 23rd October' 2020

For AARTI DRUGS LIMITED


HARSHIT M. SAVLA
(JT. Managing Director)

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF AARTI DRUGS LIMITED

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone quarterly financial results of Aarti Drugs Limited ("the company") for the quarter ended September 30, 2020 and the year to date results for the period from April 01, 2020 to September 30, 2020, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended September 30, 2020 as well as the year to date results for the period from April 01, 2020 to September 30, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.





- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

**For Kirtane & Pandit LLP,
Chartered Accountants
FRN: 105215W/W100057**



**Milind Bhave
Partner
M No. 047973**

UDIN: 20047973AAAADH7401

**Place: Mumbai.
Date: October 23, 2020**

INDEPENDENT AUDITOR'S REPORT TO THE BOARD OF DIRECTORS OF AARTI DRUGS LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of Aarti Drugs Limited ("Holding company") and its subsidiaries (holding company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2020 and for the period from April 01, 2020 to September 30, 2020 ("the Statement"), being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, the Statement:

- a. includes the results of the following entities:
 - i. Pinnacle Life Science Private Limited (Wholly-owned Subsidiary Company)
 - ii. Aarti Speciality Chemicals Limited (Wholly-owned Subsidiary Company)
 - iii. Pinnacle Life Science LLC (Wholly-owned Subsidiary Company)
 - iv. Pinnacle Chile SPA (Subsidiary Company)
- b. is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, as amended; and
- c. gives a true and fair view, in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of consolidated total comprehensive income (comprising of net profit) and other comprehensive income and other financial information for the Group for the quarter ended and half year ended September 30, 2020.



Kirtane & Pandit LLP - Chartered Accountants
Bengaluru | Hyderabad | Mumbai | Nashik | Pune

H/16, Saraswat Colony, Sitladevi Temple Road, Mahim, Mumbai - 400016, India | T: +91 22 24444119,15 / 24469713 | F: +91 22 24441147 | E: kpcamumbai@kirtanepandit.com
Regd. Office: 5th Floor, Wing A, Gopal House, S.No. 127/1B/1, Plot-A1, Opp. Harshal Hall, Pune - 411 029, India | T: +91 20 67295100, 25433104, 8764 | F: +91 20 25447603 | www.kirtanepandit.com
Kirtane & Pandit (a Partnership Firm with Registration No. MPA-3441) converted into Kirtane & Pandit LLP (a Limited Liability Partnership with LLP Registration No. AAD-6418), with effect from 27th March, 2015.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

These consolidated financial results have been prepared on the basis of the annual financial statements.

The Holding Company's Board of Directors are responsible for the preparation and presentation of these Consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.



Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the Consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters


The Consolidated Financial Results include the audited Financial Results of 2 Wholly-owned Subsidiary Companies whose interim Financial Statements / Financial Results / Financial Information reflect Group's share of total assets of Rs. 12,167.59 Lakhs as at September 30, 2020, Group's share of total revenue of Rs. 7,120.81 Lakhs and Rs. 15,233.40 Lakhs and Group's share of total net profit after tax of Rs. 525.47 Lakhs and Rs. 1,834.44 Lakhs for the quarter ended September 30, 2020 and for the period from April 01, 2020 to September 30, 2020 respectively, as considered in the Consolidated Financial Results, which have been audited by their respective independent auditors. The independent auditors' reports on interim Financial Statements / Financial Results / Financial Information of these entities have been furnished to us and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

The Consolidated Financial Results include the unaudited Financial Results of a Wholly-Owned Subsidiary and a Subsidiary Company, whose interim Financial Statements / Financial Results / Financial Information reflect Group's share of total assets of Rs. 20.61 Lakhs as at September 30, 2020, Group's share of total revenue of Rs. 0.09 and Rs. 0.11 and Group's share of total net loss of Rs. 9.09 Lakhs and Rs. 9.30 Lakhs for the quarter ended September 30, 2020 and for the period from April 01, 2020 to September 30, 2020 respectively, as considered in the Consolidated Financial Results. These unaudited interim Financial Statements / Financial Results / Financial Information have been furnished to us by the Board of Directors and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of this Subsidiary Company is based solely on such unaudited interim Financial Statements / Financial Results / Financial Information. In our opinion and according to the information and explanations given to us by the Board of Directors, these interim Financial Statements / Financial Results / Financial Information are not material to the Group.



Our opinion on the Consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors and the Financial Results / Financial Information certified by the Board of Directors.

**For Kirtane & Pandit LLP,
Chartered Accountants
FRN: 105215W/W100057**



**Milind Bhawe
Partner
M No. 047973**

UDIN: 20047973AAAADI5538

**Place: Mumbai
Date: October 23, 2020**



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref: ADL/SE/2020-21
October 23, 2020

To,
Listing/ Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
BSE CODE: 524348

To,
Listing/ Compliance Department
National Stock Exchange of India Limited,
“Exchange Plaza”, Plot No. C/1,
G Block Bandra - Kurla Complex,
Bandra (East),
Mumbai – 400051
NSE CODE: AARTIDRUGS

Dear Sir/Madam,

**Sub: Compliance of Regulation 42(1)(a) and Regulation 43 of
the SEBI (LODR) Regulations, 2015.**

We wish to inform you that Board of Directors of the Company at its Meeting held on **Friday, October 23, 2020**, has declared the Interim Dividend @ Rs. 2.5/- (25%) per Equity share for the financial year 2020-21.

Please note that as per Regulation 42(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, **Wednesday, November 04, 2020** has been fixed as ‘Record Date’ for the purpose of payment of Interim Dividend.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. No.: A54527